Host: |
Pichia |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human CCL3/MIP-1 alpha-NO-tag protein was developed from pichia and has a target region of NO-tag. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Endotoxin: |
<1EU/Mu g |
Gene Symbol: |
CCL3 |
Gene ID: |
6348 |
Uniprot ID: |
CCL3_HUMAN |
Immunogen Region: |
Ala23-Ala92 |
Immunogen: |
Recombinant Human CCL3/MIP-1 alpha Protein is produced by Pichia expression system. The target protein is expressed with sequence (Ala23-Ala92) of human CCL3/MIP-1 alpha (Accession #NP_002974.1) fused with no additional amino acid. |
Function | Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). |
Protein Name | C-C Motif Chemokine 3G0/G1 Switch Regulatory Protein 19-1Macrophage Inflammatory Protein 1-AlphaMip-1-AlphaPat 464.1Sis-BetaSmall-Inducible Cytokine A3Tonsillar Lymphocyte Ld78 Alpha Protein Cleaved Into - Mip-1-Alpha(4-69Ld78-Alpha(4-69 |
Database Links | Reactome: R-HSA-380108Reactome: R-HSA-6783783 |
Cellular Localisation | Secreted |
Alternative Protein Names | C-C Motif Chemokine 3 proteinG0/G1 Switch Regulatory Protein 19-1 proteinMacrophage Inflammatory Protein 1-Alpha proteinMip-1-Alpha proteinPat 464.1 proteinSis-Beta proteinSmall-Inducible Cytokine A3 proteinTonsillar Lymphocyte Ld78 Alpha Protein Cleaved Into - Mip-1-Alpha(4-69 proteinLd78-Alpha(4-69 proteinCCL3 proteinG0S19-1 proteinMIP1A proteinSCYA3 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance